Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 3:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 297 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fasting First Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Alprazolam Extended-Release 3mg Tablets Bioequivalence Study Under Non-fasting Conditions

NCT00830024
View directory record Official record
Conditions
Healthy
Interventions
Alprazolam Extended-Release 3 mg Tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
2
States / cities
East Grand Forks, Minnesota • Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Oct 31, 2026, 3:45 PM EDT
Terminated Not applicable Interventional Results available

Cognitive Control Training for Urgency in a Naturalistic Clinical Setting

NCT03527550
View directory record Official record
Conditions
Impulsive Behavior, Mental Disorders
Interventions
Cognitive Control Training
Other
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Oct 31, 2026, 3:45 PM EDT
Not listed Phase 1Phase 2 Interventional

Phase I/II, FIH, Dose Escalation Trial of TL-895 and Expansion of TL-895 Monotherapy and Combination Therapy With Navtemadlin in Tx-Naïve and R/R CLL/SLL Subjects

NCT02825836
View directory record Official record
Conditions
Relapsed/Refractory B Cell Malignancies, Mantle Cell Lymphoma and Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Treatment-Naive B Cell Malignancies
Interventions
TL-895, Navtemadlin
Drug
Lead sponsor
Telios Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
2
States / cities
Columbus, Ohio • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 13, 2023 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating the Relative Bioavailability of Lofexidine Granules for Reconstitution Compared to LUCEMYRA (Lofexidine) Tablets and the Effect of Food on the Bioavailability of the Lofexidine Granules for Reconstitution

NCT04188730
View directory record Official record
Conditions
Normal Healthy Volunteers
Interventions
Lofexidine (granules for reconstitution), LUCEMYRA (lofexidine) tablets
Drug
Lead sponsor
USWM, LLC (dba US WorldMeds)
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jun 15, 2022 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study to Evaluate the Pharmacokinetics and Safety of INX-08189 Administered With VictrelisTM in Healthy Subjects

NCT01471717
View directory record Official record
Conditions
Healthy
Interventions
INX-08189 50 mg QD X 5 days, INX-08189 / Victrelis 800 mg TID X three days, Victrelis 800 mg TID x 3 days, Victrelis 800 mg TID with INX-08189 50 mg QD, Placebo with Victrelis 800 mg, Cohort 2: Victrelis 800 mg with Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 31, 2026, 3:45 PM EDT
Active, not recruiting Phase 2 Interventional

Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes

NCT04542148
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk, Diabetes, Gestational
Interventions
Sliding Scale Insulin, Up-Titration of Home Insulin, Continuous Insulin Infusion, Dexcom G6 Professional Continuous Glucose Monitor
Drug · Device
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Up to 50 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
4
States / cities
Birmingham, Alabama • Portland, Oregon • Greenville, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Applying a Person-Centered Approach to Enhance Cognitive Training in Senior Living Community Residents With Mild Cognitive Impairment

NCT03292705
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
PEP, CCI
Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
60 Years and older
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
2
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 20, 2026 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions

NCT00840411
View directory record Official record
Conditions
Healthy
Interventions
Clarithromycin ER 500 mg tablets, BIAXIN® XL 500 mg tablets
Drug
Lead sponsor
Teva Pharmaceuticals USA
Industry
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 3 Interventional Results available

A Study of LY2605541 in Participants With Type 2 Diabetes Mellitus

NCT01582451
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2605541, Insulin glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
33
States / cities
Mesa, Arizona • Phoenix, Arizona • Concord, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 20, 2018 · Synced Oct 31, 2026, 3:45 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Intermittent Fasting on Body Fat and Quality of Life

NCT06307275
View directory record Official record
Conditions
Healthy
Interventions
Fasting, non fasting
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 31, 2026, 3:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Role of Alpha-to-beta Cell Communication to Adapt Insulin Secretion to Insulin Resistance.

NCT07224334
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Exendin-9 is a 30 amino acid peptide that is an established competitive antagonist of the GLP-1 receptor. Subjects will receive exendin-9 by intravenous infusion at a rate of 600 pmol/kg/min, Dexamethasone, Dextrose 20% solution
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
18 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 31, 2026, 3:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Opportunistic Screening for Prediabetes and Early Diabetes in Primary Care

NCT00787839
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Prediabetic State
Interventions
Glucose challenge test, Glucose tolerance test
Other
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years and older
Enrollment
1,939 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Decatur, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 27, 2015 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination Versus Insulin Glargine in Patients With Type 2 Diabetes

NCT02058160
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Insulin glargine/lixisenatide (HOE901/AVE0010), Insulin glargine (HOE901), Metformin (Background Drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
736 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
108
States / cities
Birmingham, Alabama • Sun City, Arizona • Tempe, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Oct 31, 2026, 3:45 PM EDT
Terminated Not applicable Interventional Results available

The Effect of Lactation on Insulin Sensitivity and Lipolysis in Women

NCT04146909
View directory record Official record
Conditions
GDM, Lactation
Interventions
Hyperinsulinemic-euglycemic clamp
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 15, 2024 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Brain Imaging Study With Positron Emission Tomography and the Radiotracer [11C]UCB-J to Estimate How Fast Brivaracetam and Levetiracetam Enter the Brain in Healthy Volunteers

NCT02602860
View directory record Official record
Conditions
Healthy Volunteers
Interventions
[11C]UCB-J, Brivaracetam, Levetiracetam
Radiation · Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Biobehavioral Impact of Diet Quality on Affect and Craving

NCT04105712
View directory record Official record
Conditions
Food Addiction, Withdrawal
Interventions
Dietary Change (low in highly processed foods)
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
25 Years to 40 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

Ph I 5-day Temozolomide + O6-BG in Treatment of Pts w Recurrent / Progressive GBM

NCT00612989
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
Temodar and O6-Benzylguanine
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 16, 2014 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Thorough QT/QTC (TQT) Clinical Trial to Evaluate the Effect of Zoliflodacin on Cardiac Repolarization in Healthy Male and Female Subjects

NCT03613649
View directory record Official record
Conditions
Electrocardiogram Repolarisation Abnormality, Gonococcal Infection
Interventions
AZD0914, Moxifloxacin, Placebo
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2020 · Synced Oct 31, 2026, 3:45 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics

NCT07169318
View directory record Official record
Conditions
Influenza
Interventions
Placebo for VNT-101, VNT-101
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 59 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluating the SWW Method Dietary Intervention for HbA1c and Weight Management as a Preventative Intervention in Women

NCT07463417
View directory record Official record
Conditions
Metabolic Syndrome, Obesity & Overweight, Blood Glucose Monitoring, Type 2 Diabetes Prevention
Interventions
SWW Method® Dietary and Lifestyle Intervention
Behavioral
Lead sponsor
Sarah Wragge Wellness
Industry
Eligibility
35 Years to 75 Years · Female only
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Oct 31, 2026, 3:45 PM EDT
Not yet recruiting Not applicable Interventional

Active Balance and Cardio Care Intervention on Physical and Cardiovascular Health in People With Chronic Stroke

NCT06060470
View directory record Official record
Conditions
Chronic Stroke
Interventions
Virtual reality based dance group, Active Comparator: Control
Behavioral
Lead sponsor
University of Illinois Chicago
Other
Eligibility
45 Years to 90 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2023 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Breathe for Hot Flashes Randomized Controlled Trial

NCT00819182
View directory record Official record
Conditions
Hot Flashes
Interventions
Paced respiration, Sham comparator: fast shallow breathing
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older · Female only
Enrollment
218 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 24, 2016 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intestinal Microecology in Chronic Constipation

NCT00934479
View directory record Official record
Conditions
Other Constipation, Irritable Bowel Syndrome
Interventions
Lubiprostone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 17, 2013 · Synced Oct 31, 2026, 3:45 PM EDT
Completed Not applicable Interventional

Fluid Resuscitation for Pediatric Diabetic Ketoacidosis

NCT01701557
View directory record Official record
Conditions
Diabetes
Interventions
slow fluid rate, fast fluid rate
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
1 Day to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 31, 2026, 3:45 PM EDT